Department of Ophthalmology, Semmelweis University, Budapest, Hungary.
Ocul Immunol Inflamm. 2023 Aug;31(6):1145-1150. doi: 10.1080/09273948.2022.2094811. Epub 2022 Aug 1.
To report a case of a patient with central retinal vein occlusion (CRVO), 2 weeks after the first dose of a COVID-19 mRNA vaccine.
A 35-year-old man presented with decreased vision on his right eye, 2 weeks after receiving the first dose of COVID-19 mRNA vaccine. During examination, signs of right CRVO were found. We started general checkup of the patient, extended with laboratory tests specific for VIPIT. No exact cause of the thromboembolic episode could be documented. With the applied therapy, symptoms resolved completely.
CRVO after COVID-19 mRNA vaccination is reported only in one case in the literature. In our case, the young age of the patient, the close onset of the symptoms to the vaccination and the negative systemic, immunologic and hematologic tests are suggesting a vaccine-induced thrombotic mechanism. We propose further investigation of vaccine-induced thrombotic mechanisms and also close follow of the reported cases.
报告 1 例 COVID-19 mRNA 疫苗接种后 2 周发生视网膜中央静脉阻塞（CRVO）的患者病例。
1 名 35 岁男性在接种 COVID-19 mRNA 疫苗第一针后 2 周出现右眼视力下降。检查发现右眼 CRVO 体征。我们对患者进行了全面检查，并进行了 VIPIT 特异性实验室检查。未发现血栓栓塞事件的确切病因。经应用治疗，症状完全缓解。
文献中仅报告了 1 例 COVID-19 mRNA 疫苗接种后发生 CRVO 的病例。在我们的病例中，患者年龄较轻，症状与疫苗接种时间密切相关，且系统、免疫和血液学检查均为阴性，提示与疫苗相关的血栓形成机制。我们建议进一步研究疫苗诱导的血栓形成机制，并密切关注已报告的病例。
